Friday, May 13, 2016

Tobira - Publication of Phase 1 Study Showing Cenicriviroc Safety in Cirrhotic Patients

Tobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients

SOUTH SAN FRANCISCO, Calif., May 13, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today announced that data from a study of cenicriviroc (CVC) in participants with liver cirrhosis and mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment, has been accepted as a manuscript for publication in the journal Clinical Translational Science. Available at:

"The results from this study are particularly relevant as we continue to explore the efficacy and safety of this dose of CVC in adults with NASH and liver fibrosis in the ongoing CENTAUR study, where over one-third of subjects had severe fibrosis at entry and are therefore at risk of progression to cirrhosis," said Eric Lefebvre, M.D., chief medical officer of Tobira. "Prior to this study, there were limited studies evaluating whether cirrhosis impacts the metabolism and safety of CCR2 or CCR5 antagonists. These study findings show that CVC, a dual CCR2/CCR5 antagonist, can be dosed at 150 milligrams once-daily in cirrhotic patients with mild-to-moderate hepatic impairment, and it was well tolerated."

The study evaluated the pharmacokinetics, pharmacodynamics and safety of CVC in participants with cirrhosis and mild or moderate hepatic impairment compared to healthy matched controls. Following once-daily administration of CVC 150 milligrams over 14 days, participants with mild hepatic impairment did not have increased exposures whereas those with moderate hepatic impairment had higher exposures (AUC0-t and Cmax increased by 55% and 29%, respectively). Exploratory analyses to evaluate pharmacodynamic effects of CVC on CCR2 and CCR5 ligands, proinflammatory cytokines and bacterial translocation biomarkers did not reveal any meaningful differences between participants with hepatic impairment and those with normal hepatic function. Furthermore, CVC was generally well tolerated, with adverse events consistent with its known safety profile.

CVC treatment resulted in rapid and reciprocal increases in the ligands CCL2 and CCL5, consistent with potent and sustained CCR2/CCR5 blockade across all treatment groups. Despite increases in CCL2 and CCL5, no significant effects on markers of hepatic inflammation or proinflammatory cytokines were observed over the 14-day treatment period.

Study DesignThis Phase 1, open-label, non-randomized, single-center study was conducted in the U.S. and enrolled participants with mild (Child–Pugh class A) or moderate (Child–Pugh class B) hepatic impairment; healthy participants with normal hepatic function were matched for age (±5 years), body weight (±15%), and gender. The study was composed of two cohorts:
  • participants with mild hepatic impairment and their matched controls with normal hepatic function ("matched controls (mild)");
  • participants with moderate hepatic impairment and their matched controls with normal hepatic function ("matched controls (moderate)").
Both cohorts were conducted in parallel.

About Cenicriviroc (CVC) and Non-alcoholic Steatohepatitis (NASH)CVC is an oral, once-daily, potent immunomodulator that blocks two chemokine receptors, CCR2 and CCR5, which are intricately involved in the inflammatory and fibrogenic pathways in NASH that cause liver damage and often lead to cirrhosis, liver cancer or liver failure. Tobira believes this novel approach will establish CVC as both a single-agent and as a cornerstone treatment in multi-therapy regimens for NASH, for which there is currently no approved drug.

CVC is currently being evaluated in Tobira's fully enrolled global Phase 2b CENTAUR study (identifier NCT02217475) and the company expects to announce the study's primary endpoint in the third quarter of 2016. CENTAUR is comparing CVC to placebo in 289 patients with NASH and liver fibrosis. CVC has been granted Fast Track status in patients with NASH and liver fibrosis, the patient population at highest risk of progression to cirrhosis. The CENTAUR study includes surrogate endpoints identified as suitable for registrational studies in findings of an FDA-AASLD workshop reported in Hepatology and in use in current Phase 3 studies. To date, over 600 subjects have been dosed in completed studies with CVC, including 115 HIV infected subjects on treatment for up to 48 weeks.

NASH is an emerging health crisis impacting 3% to 5% of the U.S. population and 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. Additionally, this population is estimated to be three to five times larger than the size of the population with hepatitis C in the U.S.

No comments:

Post a Comment